Feature | August 28, 2013

Zilver PTX Drug-Eluting Peripheral Qualifies for Additional Medicare Reimbursement

August 28, 2013 — Effective Oct. 1, Cook Medical’s Zilver PTX drug-eluting peripheral stent qualifies for new-technology add-on payments under Medicare’s hospital inpatient prospective payment system.

“This is great news for Medicare beneficiaries who suffer from peripheral arterial disease, and for U.S. hospitals that treat these patients,” said Jim Gardner, M.D., director of reimbursement and medical science officer for Cook Medical.

Zilver PTX technology had to meet three criteria to qualify for add-on reimbursement. First, a new technology must represent a substantial clinical improvement. Second, the data that Medicare uses to set payments for the new technology under the Medicare severity diagnosis-related groups (MS-DRGs) must not be available. Third, the MS-DRG payment rate that otherwise applies to the new technology must be inadequate.

The add-on reimbursement typically remains in place two to three years, at which point Medicare will determine the “permanent” diagnosis-related group assignments for Zilver PTX procedures, Gardner added. While the add-on payment is in effect, hospitals can receive up to $1,705.25 in additional reimbursement for each patient that is treated on an inpatient basis with Zilver PTX stents.

“Now that Medicare has recognized the benefits of this technology, we encourage our hospital customers to discuss similar reimbursement policies with the commercial insurance plans they contract with,” Gardner said.

This additional reimbursement is available to hospitals only for inpatient procedures. It doesn’t affect physician reimbursement, hospital reimbursement for outpatient procedures, or ambulatory surgery center (ASC) reimbursement for Zilver PTX stenting procedures performed in the ASC.

For more information: www.cookmedical.com

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init